evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/geneAliases/5,gene/geneAliases/6,gene/geneAliases/7,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract,articles/13/pmid,articles/13/title,articles/13/journal,articles/13/pubDate,articles/13/volume,articles/13/issue,articles/13/pages,articles/13/authors,articles/13/elocationId,articles/13/link,articles/13/reference,articles/13/abstract,articles/14/pmid,articles/14/title,articles/14/journal,articles/14/pubDate,articles/14/volume,articles/14/issue,articles/14/pages,articles/14/authors,articles/14/elocationId,articles/14/link,articles/14/reference,articles/14/abstract,articles/15/pmid,articles/15/title,articles/15/journal,articles/15/pubDate,articles/15/volume,articles/15/issue,articles/15/pages,articles/15/authors,articles/15/elocationId,articles/15/link,articles/15/reference,articles/15/abstract,articles/16/pmid,articles/16/title,articles/16/journal,articles/16/pubDate,articles/16/volume,articles/16/issue,articles/16/pages,articles/16/authors,articles/16/elocationId,articles/16/link,articles/16/reference,articles/16/abstract,articles/17/pmid,articles/17/title,articles/17/journal,articles/17/pubDate,articles/17/volume,articles/17/issue,articles/17/pages,articles/17/authors,articles/17/elocationId,articles/17/link,articles/17/reference,articles/17/abstract,articles/18/pmid,articles/18/title,articles/18/journal,articles/18/pubDate,articles/18/volume,articles/18/issue,articles/18/pages,articles/18/authors,articles/18/elocationId,articles/18/link,articles/18/reference,articles/18/abstract
6731,GENE_BACKGROUND,,"ERBB2, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is aberrantly amplified and/or overexpressed in a range of human cancers, including breast, gastric/gastroesophageal and endometrial tumors (PMID:19536107). ERBB2/HER2 is unique in that it does not directly bind its own ligand. Instead, it potentiates the activity of other ligand-bound ERBB receptors such as EGFR (ERBB1) or ERBB3 by binding to them (PMID:12620236). Indeed, ERBB2 is the preferred binding partner for all ERBB receptor isoforms (PMID:10220407, 9130710) and ERBB2/ERBB3 complexes have shown high mitogenic activity through the activation of downstream oncogenic PI3K pathway (PMID: 12853564). Alternatively, ERBB2 may homodimerize and initiate intracellular mitogenic cascades including RAS/MAPK, PI3K/AKT/mTOR, SRC and STAT signaling pathways (PMID: 22785351). Approximately 17% to 30% of human breast tumors harbor ERBB2 gene amplification, which is associated with poor overall survival and time to tumor recurrence (PMID: 3798106, 23000897,9552035, 9469329). Amplified ERBB2 heterodimerizes with ERBB3 to activate PI3K/AKT/mTOR signaling and drive tumorigenesis in breast cancer (PMID:12853564, 23204226, 12124352, 18632642). ERBB2 is also amplified in about 20% of gastric or gastroesophageal cancers (PMID: 24943493, 21468131), and its overexpression is targeted by multiple available drugs (e.g., trastuzumab, ado-trastuzumab emtansine, lapatanib, and pertuzumab) (PMID:24799465). There is a low incidence of ERBB2 amplification in non-small cell lung, ovarian, bladder, cervical, endometrial, colorectal, pancreatic and salivary duct cancers and soft tissue sarcoma, and anecdotally in cholangiocarcinoma (reviewed in PMID: 24656976). Activating ERBB2 mutations have recently been identified at lower frequency in many cancers, including lung adenocarcinoma, lobular breast, bladder, gastric and endometrial cancers, with recurrent hotspot alterations in both the extracellular and kinase domains (PMID: 23000897, 23220880, 22908275). Preclinical studies have demonstrated that many of these mutations are transforming and sensitive to FDA approved ERBB targeted therapies. Clinical trials are underway in ERBB2 mutant cohorts, with some positive evidence of the efficacy of ERBB2 targeted kinase inhibitors. ERBB2 mutations in colorectal cancer often co-occur with mutations in RAS.",,2017-07-24,,2064,ERBB2,erb-b2 receptor tyrosine kinase 2,True,ENST00000269571,NM_004448.2,CD340,MLN 19,TKR1,NGL,HER-2/neu,HER2,HER-2,NEU,False,12853564,The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.,Proceedings of the National Academy of Sciences of the United States of America,2018-07-22T20:03:00,100,15,8933-8,Holbro T et al,,,0001-07-22,,24656976,HER2 aberrations in cancer: implications for therapy.,Cancer treatment reviews,2018-07-01T20:14:00,40,6,770-80,Yan M et al,doi: 10.1016/j.ctrv.2014.02.008,,0001-07-01,,10220407,0001-05-01,Proceedings of the National Academy of Sciences of the United States of America,0001-04-27,96,9,4995-5000,Klapper LN et al,,,0001-04-27,,23204226,Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.,Cancer research,2018-02-01T20:13:00,73,3,1190-200,Chakrabarty A et al,doi: 10.1158/0008-5472.CAN-12-2440,,2018-02-01T02:00:00,,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,Proceedings of the National Academy of Sciences of the United States of America,2018-09-04T20:12:00,109,36,14476-81,Greulich H et al,doi: 10.1073/pnas.1203201109,,0001-09-04,,9130710,"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.",The EMBO journal,0001-04-01,16,7,1647-55,Graus-Porta D et al,,,0001-04-01,,12124352,"Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.",Cancer research,2018-07-15T20:02:00,62,14,4132-41,Yakes FM et al,,,0001-07-15,,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,Cancer discovery,2018-02-01T20:13:00,3,2,224-37,Bose R et al,doi: 10.1158/2159-8290.CD-12-0349,,0001-02-01,,21468131,Targeting the human EGFR family in esophagogastric cancer.,Nature reviews. Clinical oncology,2018-04-05T20:11:00,8,8,492-503,Okines A et al,doi: 10.1038/nrclinonc.2011.45,,2018-04-05T05:03:00,,9552035,neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,0001-04-01,16,4,1340-9,Andrulis IL et al,,,0001-04-01,,12620236,"The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.",Molecular cell,2018-02-01T20:03:00,11,2,495-505,Garrett TP et al,,,2018-02-01T05:05:00,,18632642,A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.,Cancer research,2018-07-15T20:08:00,68,14,5878-87,Lee-Hoeflich ST et al,doi: 10.1158/0008-5472.CAN-08-0380,,0001-07-15,,24943493,"A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.",Cancer letters,2018-08-28T20:14:00,351,True,30-40,Gomez-Martín C et al,doi: 10.1016/j.canlet.2014.05.019,,0001-08-28,,3798106,Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.,"Science (New York, N.Y.)",0001-01-09,235,4785,177-82,Slamon DJ et al,,,0001-01-09,,23000897,Comprehensive molecular portraits of human breast tumours.,Nature,2018-10-04T20:12:00,490,7418,61-70,Cancer Genome Atlas Network.,doi: 10.1038/nature11412,,0001-10-04,,9469329,"Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,0001-02-01,16,2,462-9,Sjögren S et al,,,0001-02-01,,24799465,Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2018-07-01T20:14:00,32,19,2078-99,Giordano SH et al,doi: 10.1200/JCO.2013.54.0948,,0001-07-01,,19536107,Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.,Nature reviews. Cancer,2018-07-01T20:09:00,9,7,463-75,Baselga J et al,doi: 10.1038/nrc2656,,0001-07-01,,22785351,"The ERBB network: at last, cancer therapy meets systems biology.",Nature reviews. Cancer,2018-07-12T20:12:00,12,8,553-63,Yarden Y et al,doi: 10.1038/nrc3309,,0001-07-12,
6730,GENE_SUMMARY,,"ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.",,2017-04-19,,2064,ERBB2,erb-b2 receptor tyrosine kinase 2,True,ENST00000269571,NM_004448.2,CD340,MLN 19,TKR1,NGL,HER-2/neu,HER2,HER-2,NEU,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
